Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells

Molecular Cancer Therapeutics

Volumn 8, Issue 5, 2009, Pages 1340-1349

  Vander Griend, Donald J ^a   Antony, Lizamma ^a   Dalrymple, Susan L ^a   Xu, Yi ^a   Christensen, S Brogger ^b   Denmeade, Samuel R ^a   Isaacs, John T ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 O (12 DODECANYL) 8 O DEBUTANOYL THAPSIGARGIN; ALANYL 8 O (12 DODECANYL) 8 O DEBUTANOYL THAPSIGARGIN; AMINO ACID; ANDROGEN RECEPTOR; ASPARTYL 8 O (12 DODECANYL) 8 O DEBUTANOYL THAPSIGARGIN; CALCIUM ION; LEUCYL 8 O (12 DODECANYL) 8 O DEBUTANOYL THAPSIGARGIN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SEPRASE; SERCA 2B PROTEIN; SESQUITERPENE LACTONE; THAPSIGARGIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CALCIUM DEPLETION; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL STRAIN CWR22RV1; CELL STRAIN LAPC 4; CELL STRAIN LNCAP; CELL STRAIN VCAP; CONTROLLED STUDY; DRUG STRUCTURE; ENDOPLASMIC RETICULUM STRESS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IMMUNOCYTOCHEMISTRY; LD 50; LIPOPHILICITY; MDA PC 2B CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CALCIUM; CELL DEATH; CELL LINE, TUMOR; DNA-BINDING PROTEINS; ENDOPLASMIC RETICULUM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; PHOSPHOPROTEINS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RABBITS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; THAPSIGARGIN; TRANSCRIPTION FACTORS;

EID: 66849140921     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-1136     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy programd. Cancer Res 2004;64:9209-9216 (Pubitemid 39665537)
3. van Bokhoven A, Varella-Garcia M, Korch C, et al. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003;57:205-225 (Pubitemid 37267805)
4. Yang Q, Fung KM, Day WV, Kropp BP, Lin HK. Androgen receptor signalingis required for androgen-sensitive human prostate cancer cell proliferation and survival. Cancer Cell Int 2005;5:8. (Pubitemid 40617770)
5. Dehm SM, Tindall DJ. Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol 2007;21:2855-2863 (Pubitemid 350223500)
6. Ellis WJ, Isaacs JT. Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas. Cancer Res 1985;45:6041-6050 (Pubitemid 16224757)
7. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11:4653-4657 (Pubitemid 41557182)
8. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intra-tumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447-4454
9. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-39 (Pubitemid 38524696)
10. Hobisch A, Eder IE, Putz T, et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998;58:4640-4645 (Pubitemid 28480629)
11. Chen T, WangLH, Farrar WL. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 2000;60:2132-2135 (Pubitemid 30225173)
12. Ueda T, Mawji NR, Bruchovsky N, Sadar MD. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 2002;277:38087-38094 (Pubitemid 35157768)
13. Guo Z, Dai B, Jiang T, et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 2006;10:309-319 (Pubitemid 44512189)
14. Wang Y, Kreisberg JI, Ghosh PM. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr Cancer Drug Targets 2007;7:591-604. (Pubitemid 47358145)
15. Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;9:401-406
16. Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997;57:314-319 (Pubitemid 27036612)
17. Edwards J, Krishna NS, Grigor KM, Bartlett JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003;89:552-556 (Pubitemid 37026442)
18. Ford OH, III, Gregory CW, Kim D, Smitherman AB, Mohler JL. Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J Urol 2003;170:1817-1821 (Pubitemid 37254935)
19. Taplin ME. Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol 2007;4:236-244 (Pubitemid 46510533)
20. Jagla M, Feve M, Kessler P, et al. A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions. Endocrinology 2007;148:4334-4343 (Pubitemid 47295699)
21. Lapouge G, Marcias G, Erdmann E, et al. Specific properties of a C-terminal truncated androgen receptor detected in hormone refractory prostate cancer. Adv Exp Med Biol 2008;617:529-534
22. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008;68:5469-5477
23. Kyprianou N, English HF, Isaacs JT. Activation of a Ca2+-Mg2+-dependent endonuclease as an early event in castration-induced prostatic cell death. Prostate 1988;13:103-117 (Pubitemid 18245155)
24. Martikainen P, Isaacs J. Role of calcium in the programmed death of rat prostatic glandular cells. Prostate 1990;17:175-187
25. Martikainen P, Kyprianou N, Tucker RW, Isaacs JT. Programmed death of nonproliferatinga ndrogen-independent prostatic cancer cells. Cancer Res 1991;51:4693-4700
26. Furuya Y, Lundmo P, Short AD, Gill DL, Isaacs JT. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by TG. Cancer Res 1994;54:6167-6175 (Pubitemid 24378650)
27. Thastrup O, Cullen PJ, Drobak BK, Hanley MR, Dawson AP. Thapsigargin, a tumor promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2(+)-ATPase. Proc Natl Acad Sci U S A 1990;87:2466-2470
28. Tombal B, Denmeade SR, Isaacs JT. Assessment and validation of a microinjection method for kinetic analysis of [Ca2+]i in individual cells undergoing apoptosis. Cell Calcium 1999;25:19-28. (Pubitemid 29083988)
29. Gong Y, Blok LJ, Perry JE, Lindzey JK, Tindall DJ. Calcium regulation of androgen receptor expression in the human prostate cancer cell line LNCaP. Endocrinology 1995;136:2172-2178
30. Christensen SB, Andersen A, Kromann H, et al. Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells. Bioorg Med Chem 1999;7:1273-1280 (Pubitemid 29292369)
31. Jakobsen CM, Denmeade SR, Isaacs JT, et al. Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells. J Med Chem 2001;44:4696-4703 (Pubitemid 33144479)
32. Denmeade SR, Jakobsen CM, Janssen S, et al. Prostate-specific antigen- activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst 2003;95:990-1000. (Pubitemid 36896716)
33. Singh P, Mhaka AM, Christensen SB, et al. Applying linear interaction energy method for rational design of noncompetitive allosteric inhibitors of the sarco- and endoplasmic reticulum calcium-ATPase. J Med Chem 2005;48:3005-3014 (Pubitemid 40548112)
34. Sohoel H, Jensen AM, Moller JV, et al. Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate cancer cells. Bioorg Med Chem 2006;14:2810-2815 (Pubitemid 43343668)
35. Denmeade SR, Isaacs JT. The SERCA pump as a therapeutic target: makinga "smart bomb" for prostate cancer. Cancer Biol Ther 2005;4:14-22.
36. Aggarwal S, Brennen WN, Kole TP, et al. Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites. Biochemistry 2008;47:1076-1086
37. Dalrymple S, Antony L, Xu Y, et al. Role of notch-1 and E-cadherin in the differential response to calcium in culturingnormal versus malignant prostate cells. Cancer Res 2005;65:9269-9279 (Pubitemid 41507993)
38. Iwawaki T, Akai R, Kohno K, Miura M. A transgenic mouse model for monitoring endoplasmic reticulum stress. Nat Med 2004;10:98-102. (Pubitemid 38524705)
39. Tombal B, Denmeade SR, Gillis JM, Isaacs JT. A supramicromolar elevation of intracellular free calcium ([Ca(2+)](i)) is consistently required to induce the execution phase of apoptosis. Cell Death Differ 2002;9:561-573
40. Lin XS, Denmeade SR, Cisek L, Isaacs JT. Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin. Prostate 1997;33:201-207 (Pubitemid 27509421)
41. Denmeade SR, Lin XS, Tombal B, Isaacs JT. Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate cancer cells. Prostate 1999;39:269-279 (Pubitemid 29244501)
42. Tombal B, Weeraratna AT, Denmeade SR, Isaacs JT. Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells. Prostate 2000;43:303-317 (Pubitemid 30367966)
43. Korenchuk S, Lehr JE, L MC, et al. VCaP, a cell-based model system of human prostate cancer. In Vivo 2001;15:163-168 (Pubitemid 32328191)
44. Cinar B, De Benedetti A, Freeman MR. Post-transcriptional regulation of the androgen receptor by Mammalian target of rapamycin. Cancer Res 2005;65:2547-2553 (Pubitemid 40490049)
45. Marissen WE, Lloyd RE. Eukaryotic translation initiation factor 4G is targeted for proteolytic cleavage by caspase 3 during inhibition of translation in apoptotic cells. Mol Cell Biol 1998;18:7565-7574 (Pubitemid 28533075)
46. Soldani C, Scovassi AI. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 2002;7:321-328
47. Kimura K, Markowski M, Bowen C, Gelmann EP. Androgen blocks apoptosis of hormone-dependent prostate cancer cells. Cancer Res 2001;61:5611-5618 (Pubitemid 32700276)
48. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103-106 (Pubitemid 34786197)
49. Liao X, Tang S, Thrasher JB, Griebling TL, Li B. Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther 2005;4:505-515 (Pubitemid 40601831)
50. Rosini P, Bonaccorsi L, Baldi E, et al. Androgen receptor expression induces FGF2, FGF-bindingprotein production, and FGF2 release in prostate carcinoma cells: role of FGF2 in growth, survival, and androgen receptor down-modulation. Prostate 2002;53:310-321 (Pubitemid 35398501)